Advisory EditorImmunotherapy with nivolumab and pembrolizumab or a combination therapy have shown improvements in the survival of patients with squamous non-small-cell lung cancer. With many immunotherapeutic agents in the developmental phase, assigning patients to the best therapy will become ever more important and challenging.
Advisory EditorBiomarker testing has opened the door for precision medicine based on an individual patient’s tumor characteristics rather than histology alone. Key biomarkers in patients with advanced non-small-cell lung cancer are epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, KRAS mutations or programmed death-ligand 1 (PD-L1) expression. Limitations to this approach, e.g. the sensitivity of the diagnostic tools or tissue availability, should be overcome by modern molecular technologies.
- In this video, Martin Reck, Head of the Oncology unit, LungenClinic Grosshansdorf, Germany, discusses the emergence of immunotherapy and the positive results of four randomized trials on immunotherapy vs. chemotherapy, showing benefit in overall survival. He also mentions that immunotherapy might work better than chemotherapy in selected patients and reviews treatment options for a specific population of patients with autoimmune diseases at baseline.
- Therapy of EGFR-mutated lung cancer was discussed in detail during the World Conference on Lung Cancer held in Vienna, including recent data. Federico Cappuzzo, Director Medical Oncology Department at Ospedale Civile, Livorno, Italy, provides insights into the management of EGFR-mutated NSCLC with the new molecule osimertinib and reviews the benefits and limitations of liquid biopsy.